Article Details

FDA Grants Fast Track Status to PDS0101 Plus Pembrolizumab for Recurrent/Metastatic ...

Retrieved on: 2022-06-02 20:30:35

Tags for this article:

Click the tags to see associated articles and topics

FDA Grants Fast Track Status to PDS0101 Plus Pembrolizumab for Recurrent/Metastatic .... View article details on hiswai:

Excerpt

Sponsor: PDS Biotechnology Corp. and Merck Sharp & Dohme LLC. Recruitment Contact: Lauren V Wood, MD of PDS Biotechnology Corporation.

Article found on: www.targetedonc.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up